https://www.nasdaq.com/press-release/alimera-sciences-to-participate-in-upcoming-january-2022-investor-conferences-2022-01
https://www.nasdaq.com/press-release/alimera-sciences-welcomes-ophthalmic-strategic-consultant-erin-parsons-to-its-board
https://www.nasdaq.com/press-release/alimera-sciences-to-participate-in-upcoming-november-2021-investor-conferences-2021
https://www.nasdaq.com/press-release/alimera-sciences-announces-third-quarter-2021-financial-results-2021-10-28
https://www.nasdaq.com/press-release/alimera-sciences-to-report-third-quarter-2021-financial-results-on-thursday-october
https://www.nasdaq.com/press-release/recent-24-month-real-world-paladin-data-demonstrate-the-ability-of-iluvienr-to
https://www.nasdaq.com/press-release/alimera-sciences-inc.-to-present-at-the-h.c.-wainwright-23rd-annual-global-investment
https://www.nasdaq.com/press-release/alimera-sciences-announces-national-pricing-and-reimbursement-granted-for-iluvienr
https://www.nasdaq.com/press-release/alimera-sciences-announces-second-quarter-2021-financial-results-2021-08-13
https://www.nasdaq.com/press-release/alimera-sciences-to-report-second-quarter-2021-financial-results-on-friday-august-13
https://www.nasdaq.com/press-release/alimera-sciences-and-tanner-pharma-group-initiate-global-named-patient-program-for
https://www.nasdaq.com/press-release/35-of-the-best-ideas-companies-to-present-at-the-summer-solstice-best-ideas-from-the
https://www.nasdaq.com/press-release/alimera-sciences-inc.-to-present-at-the-summer-solstice-best-ideas-from-the-buy-side
https://www.nasdaq.com/press-release/alimera-sciences-appoints-david-dyer-m.d.-as-chief-retina-specialist-2021-05-17
https://www.nasdaq.com/press-release/alimera-sciences-announces-first-quarter-2021-financial-results-2021-04-28
https://www.nasdaq.com/press-release/alimera-sciences-to-report-first-quarter-2021-financial-results-on-wednesday-april-28
https://www.nasdaq.com/press-release/alimera-sciences-receives-%2420-million-from-ocumension-therapeutics-2021-04-14
https://www.nasdaq.com/press-release/alimera-sciences-to-present-at-the-zooming-with-ld-micro-virtual-conference-on-april
https://www.nasdaq.com/press-release/alimera-sciences-to-participate-in-benzinga-biotech-small-cap-conference-2021-03-18
https://www.nasdaq.com/press-release/alimera-sciences-continues-to-execute-on-its-expansion-strategy-in-denmark-and
https://www.nasdaq.com/press-release/alimera-sciences-to-present-at-maxim-groups-inaugural-emerging-growth-virtual
https://www.nasdaq.com/press-release/alimera-sciences-to-present-at-the-h.c.-wainwright-global-life-sciences-conference
https://www.nasdaq.com/press-release/alimera-sciences-reports-fourth-quarter-and-2020-results-2021-02-24
https://www.nasdaq.com/press-release/alimera-sciences-continues-global-geographic-expansion-with-launch-of-iluvien-in
https://www.nasdaq.com/press-release/alimera-sciences-to-report-fourth-quarter-and-full-year-2020-financial-results-on
https://www.nasdaq.com/press-release/alimera-sciences-to-present-at-the-microcap-rodeo-winter-wonderland-conference-2021
https://www.nasdaq.com/press-release/alimera-sciences-inc.-discusses-its-2021-global-expansion-strategy-with-the-stock-day
https://www.nasdaq.com/press-release/alimera-sciences-announces-preliminary-top-line-results-for-fourth-quarter-and-full
https://www.nasdaq.com/press-release/alimera-sciences-to-present-at-the-h.c.-wainwright-bioconnect-2021-virtual-conference
https://www.nasdaq.com/press-release/alimera-sciences-announces-launch-of-iluvienr-in-the-netherlands-2020-12-09
https://www.nasdaq.com/press-release/alimera-sciences-to-present-at-the-13th-annual-ld-micro-main-event-virtual-conference
https://www.nasdaq.com/press-release/alimera-sciences-announces-participation-at-the-11th-annual-craig-hallum-alpha-select
https://www.nasdaq.com/press-release/alimera-sciences-announces-real-world-clinical-data-for-iluvienr-to-be-presented-at
https://www.nasdaq.com/press-release/alimera-sciences-announces-third-quarter-2020-financial-results-2020-10-28
https://www.nasdaq.com/press-release/alimera-sciences-to-report-third-quarter-2020-financial-results-on-wednesday-october
https://www.nasdaq.com/press-release/alimera-sciences-announces-multiple-posters-and-papers-highlighting-the-durability-of
https://www.nasdaq.com/press-release/alimera-sciences-signs-distribution-agreement-with-medis-pharmaceutical-to
https://www.nasdaq.com/press-release/alimera-sciences-announces-participation-at-the-h.c.-wainwright-22nd-annual-global
https://www.nasdaq.com/press-release/alimera-sciences-obtains-reimbursement-approval-for-iluvienr-use-in-non-infectious
https://www.nasdaq.com/press-release/alimera-sciences-announces-enrollment-of-first-patient-in-landmark-new-day-clinical
https://www.nasdaq.com/press-release/ld-micro-360-companies-set-to-present-this-week-2020-08-31
https://www.nasdaq.com/press-release/alimera-sciences-announces-national-reimbursement-granted-for-iluvienr-in-the
https://www.nasdaq.com/press-release/alimera-sciences-to-present-at-the-ld-micro-500-virtual-conference-on-september-2
https://www.nasdaq.com/press-release/alimera-sciences-signs-distribution-agreement-with-nordic-prime-to-expand
https://www.nasdaq.com/press-release/ld-micro-announces-preliminary-list-of-presenters-for-the-ld-500-2020-08-05
https://www.nasdaq.com/press-release/alimera-sciences-announces-second-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/alimera-sciences-to-report-second-quarter-2020-financial-results-on-wednesday-july-29
https://www.nasdaq.com/press-release/alimera-sciences-initiates-landmark-new-day-clinical-trial-to-evaluate-iluvienr-as
https://www.nasdaq.com/press-release/alimera-to-present-at-the-june-2020-virtual-summer-investor-summit-2020-06-03
https://www.nasdaq.com/press-release/alimera-sciences-announces-first-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/alimera-sciences-to-report-first-quarter-2020-financial-results-on-wednesday-april-29
https://www.nasdaq.com/press-release/alimera-sciences-receives-%241.8-million-loan-under-the-paycheck-protection-act-2020-04
https://www.nasdaq.com/press-release/alimera-sciences-pre-announces-expected-top-line-revenue-for-q1-2020-and-provides
https://www.nasdaq.com/press-release/alimera-sciences-appoints-steven-t.-gill-to-the-newly-created-position-of-vice
https://www.nasdaq.com/press-release/alimera-sciences-data-available-for-the-11th-annual-congress-on-controversies-in
https://www.nasdaq.com/press-release/alimera-sciences-reports-record-fourth-quarter-and-2019-results-2020-02-26
https://www.nasdaq.com/press-release/alimera-sciences-meets-revenue-milestone-and-accesses-additional-%242.5-million-under
https://www.nasdaq.com/press-release/alimera-sciences-to-report-fourth-quarter-and-full-year-2019-financial-results-on
https://www.nasdaq.com/press-release/alimera-sciences-refinances-its-debt-facility-with-solar-capital-2020-01-06
https://www.nasdaq.com/press-release/almira-sciences-inc-13d-filing-2019-12-11
https://www.nasdaq.com/press-release/alimera-sciences-to-participate-in-the-ld-micro-12th-annual-main-event-on-december-10
https://www.nasdaq.com/press-release/alimera-announces-regulatory-approval-for-iluvienr-in-benelux-countries-for-the
https://www.nasdaq.com/press-release/alimera-sciences-to-participate-in-the-31st-annual-piper-jaffray-healthcare
https://www.nasdaq.com/press-release/alimera-sciences-announces-effectiveness-of-previously-announced-reverse-stock-split
https://www.nasdaq.com/press-release/alimera-sciences-terminates-equity-purchase-agreement-2019-11-13
https://www.nasdaq.com/press-release/alimera-sciences-announces-boards-approval-of-reverse-stock-split-ratio-2019-11-07
https://www.nasdaq.com/press-release/alimera-sciences-to-participate-in-the-10th-annual-craig-hallum-alpha-select
https://www.nasdaq.com/press-release/alimera-sciences-announces-third-quarter-2019-financial-results-and-provides
https://www.nasdaq.com/press-release/alimera-sciences-announces-equity-purchase-agreement-for-up-to-%2420-million-with
https://www.nasdaq.com/press-release/alimera-sciences-to-report-third-quarter-2019-financial-results-on-tuesday-october-29
https://www.nasdaq.com/press-release/alimera-obtains-marketing-authorization-for-iluvienr-in-portugal-for-the-treatment-of
https://www.nasdaq.com/press-release/alimera-sciences-announces-top-line-revenue-expectation-for-the-third-quarter-of-2019
